Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIAL Trial: Obinutuzumab + MMF + Corticosteroids for Active Lupus Nephritis
NCT07767188Phase 3Not yet recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Sep 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in lupus nephritis (LN), sponsored by Minghui Pharmaceutical, Inc.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07767188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767188.